• All
  • Articles
  • Squawks
  • Trade views
  • Must reads
  • Videos
  • Calendar
Write a Squawk
No posts
  • Trade view / 21 June 2017 at 13:03 GMT
    Short term

    UPDATE: Pfizer options trade approaches target —#SaxoStrats

    Product Manager, Options Trader, Educator
    The NYSE biotechnology index climbed to a new high of 3,878 points yesterday, helping our bullish position in Pfizer. We are getting close to the take-profit target on this options trade. Our call position closed at $1.67, and investors could set a stop loss at the call's $1.10 purchase price.
    Read the Trade View
    ChristianK ChristianK
    Good call so far. I am not able to set a stop loss on the long call option. The platform will only allow input of a take...
    Georgio Stoev Georgio Stoev
    oops, we took the type of order out earlier this year. Will re-install soon. In process of creating new algos for various orders.
    ChristianK ChristianK
    Got it. Thx
  • Editor’s Picks / 06 April 2016 at 5:31 GMT

    Pfizer, Allergan to mutually terminate merger

    Sky News
    US drug maker Pfizer has agreed to terminate its $160 billion agreement to acquire Botox maker Allergan, in a major victory to US President Barack Obama's drive to stop tax-dodging corporate mergers. The decision to end the biggest tax 'inversion' ever attempted, which would have seen Pfizer slash its tax bill by redomiciling to Ireland where Allergan is registered, came a day after the US Treasury unveiled new rules to curb inversions. While these new rules did not name Pfizer and Allergan, one of their provisions targeted a specific feature of their merger: Allergan's previous history as a major acquirer of other companies.
    Read article on Sky News
    Go to post
  • Editor’s Picks / 23 November 2015 at 21:57 GMT

    Pfizer and Allergan agree to $160bn merger

    Pfizer will buy Allergan for $363.63 a share, or about $160 billion in the biggest deal ever in the health sector. It said it will likely relocate its global headquarters from New York to Ireland, a move that will cut the drug giant's US tax burden. Fred Imbert writes the deal represents a premium of over 30% based on the price of the companies' unaffected shares as of October 28. Allergan shareholders will receive 11.3 shares of the combined company – Pfizer PLC – for each Allergan share, while current Pfizer shareholders will receive one share of the new company for each share they own. The deal, the largest ever in the healthcare sector, is expected to close in the second half of next year.
    Read article on CNBC
    Go to post